Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) EV-to-EBIT : -3.38 (As of Apr. 28, 2024)

Santhera Pharmaceuticals Holding AG EV-to-EBIT Chart

Santhera Pharmaceuticals Holding AG Annual Data
	Trend	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22
EV-to-EBIT		Get a 7-Day Free Trial					-2.11	-12.61	-1.81	-2.29	-2.66

Santhera Pharmaceuticals Holding AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial															-	-2.29	-	-2.66	-

Competitive Comparison of Santhera Pharmaceuticals Holding AG's EV-to-EBIT

For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Santhera Pharmaceuticals Holding AG's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-EBIT falls into.

Santhera Pharmaceuticals Holding AG EV-to-EBIT Calculation

Santhera Pharmaceuticals Holding AG's EV-to-EBIT for today is calculated as:

Santhera Pharmaceuticals Holding AG's current Enterprise Value is $165.21 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-48.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG  (OTCPK:SPHDF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Santhera Pharmaceuticals Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Santhera Pharmaceuticals Holding AG's Enterprise Value for the quarter that ended in Jun. 2023 was $106.77 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-48.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santhera Pharmaceuticals Holding AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Santhera Pharmaceuticals Holding AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Santhera Pharmaceuticals Holding AG (Santhera Pharmaceuticals Holding AG) Business Description